Quality of New Domestic Hand Sanitizer Drug Product Manufacturers During COVID-19
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply..
The FDA initiated a cross-sectional, statistically based sampling and testing study to characterize the quality of marketed alcohol-based hand sanitizer (ABHS) by evaluating the alcohol content and impurities present in ABHS products manufactured by establishments that registered with the FDA during March-April 2020. A stratified sampling design divided the population of manufacturers into independent groups based on each establishment's level of experience with FDA oversight and its geographic location. ABHS products were collected and analyzed by spatially offset Raman spectroscopy and gas chromatography with mass spectrometry (GC-MS). The GC-MS results for 310 products, from 196 newly registered domestic manufacturers, showed that 71.6% (± 5.7%) of these manufacturers had violative products. In 104 (33.5%) cases, the alcohol content did not meet label claim assay specifications but still fell within CDC efficacy ranges. Ethanol ABHS products failed more often overall (assay and impurities) (84.3%) and for impurities (84.3%), than isopropanol ABHS products (11.2% and 6.2%, respectively). Differences in test results across active ingredients were statistically significant. Ethanol ABHS products often (63.5% of cases) failed due to the presence of acetal or acetaldehyde, particularly in products with pH ≤ 6. Other impurities were also detected in several ABHS products, suggesting the use of low-grade alcohol in the manufacture of these products. Evidence was insufficient to conclude that having experience manufacturing FDA-regulated products, or lack thereof, influenced product-level violative results. This study highlights the importance of sourcing and testing active pharmaceutical ingredients to produce quality drug products.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
The AAPS journal - 26(2023), 1 vom: 19. Dez., Seite 7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stafford, Michelle [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.12.2023 Date Revised 08.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1208/s12248-023-00877-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366054589 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366054589 | ||
| 003 | DE-627 | ||
| 005 | 20240409232305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12248-023-00877-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM366054589 | ||
| 035 | |a (NLM)38114792 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stafford, Michelle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quality of New Domestic Hand Sanitizer Drug Product Manufacturers During COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2023 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. | ||
| 520 | |a The FDA initiated a cross-sectional, statistically based sampling and testing study to characterize the quality of marketed alcohol-based hand sanitizer (ABHS) by evaluating the alcohol content and impurities present in ABHS products manufactured by establishments that registered with the FDA during March-April 2020. A stratified sampling design divided the population of manufacturers into independent groups based on each establishment's level of experience with FDA oversight and its geographic location. ABHS products were collected and analyzed by spatially offset Raman spectroscopy and gas chromatography with mass spectrometry (GC-MS). The GC-MS results for 310 products, from 196 newly registered domestic manufacturers, showed that 71.6% (± 5.7%) of these manufacturers had violative products. In 104 (33.5%) cases, the alcohol content did not meet label claim assay specifications but still fell within CDC efficacy ranges. Ethanol ABHS products failed more often overall (assay and impurities) (84.3%) and for impurities (84.3%), than isopropanol ABHS products (11.2% and 6.2%, respectively). Differences in test results across active ingredients were statistically significant. Ethanol ABHS products often (63.5% of cases) failed due to the presence of acetal or acetaldehyde, particularly in products with pH ≤ 6. Other impurities were also detected in several ABHS products, suggesting the use of low-grade alcohol in the manufacture of these products. Evidence was insufficient to conclude that having experience manufacturing FDA-regulated products, or lack thereof, influenced product-level violative results. This study highlights the importance of sourcing and testing active pharmaceutical ingredients to produce quality drug products | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a alcohol-based hand sanitizer | |
| 650 | 4 | |a ethanol-based hand sanitizer | |
| 650 | 4 | |a isopropanol-based hand sanitizer | |
| 650 | 4 | |a new domestic hand sanitizer drug manufacturers | |
| 650 | 4 | |a pharmaceutical quality | |
| 650 | 4 | |a public health emergency | |
| 650 | 7 | |a Hand Sanitizers |2 NLM | |
| 650 | 7 | |a Ethanol |2 NLM | |
| 650 | 7 | |a 3K9958V90M |2 NLM | |
| 650 | 7 | |a Acetaldehyde |2 NLM | |
| 650 | 7 | |a GO1N1ZPR3B |2 NLM | |
| 700 | 1 | |a Dunn, Rachel Linck |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Nirzari |e verfasserin |4 aut | |
| 700 | 1 | |a Kakarla, Raghavi |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkpatrick, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Magparangalan, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Ngo, Diem |e verfasserin |4 aut | |
| 700 | 1 | |a Gryniewicz-Ruzicka, Connie |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Anjanette |e verfasserin |4 aut | |
| 700 | 1 | |a Stark, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Huzeyfe |e verfasserin |4 aut | |
| 700 | 1 | |a Woodruff, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Manibusan, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Stiber, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Viehmann, Alex |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The AAPS journal |d 2004 |g 26(2023), 1 vom: 19. Dez., Seite 7 |w (DE-627)NLM154144304 |x 1550-7416 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:1 |g day:19 |g month:12 |g pages:7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1208/s12248-023-00877-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 1 |b 19 |c 12 |h 7 | ||